T Cell News and Research

Latest T Cell News and Research

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Genzyme Corporation announced today that the terms for the consent decree regarding the Allston manufacturing plant have been finalized. These terms are in line with the company's expectations announced last month. The consent decree is subject to approval by the United States District Court for the District of Massachusetts.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

A unique multi-modal atlas of human brain

The Allen Institute for Brain Science announced today that it has launched the Allen Human Brain Atlas, a publicly available online atlas charting genes at work throughout the human brain.

25 May 2010

Advances in health IT

The New York Times: A "broad transformation in health care underway" is "fueled in good part by technology" that "promises to shift a lot of the diagnosis, monitoring and treatment of disease from hospitals and specialized clinics, where treatment is expensive, to primary care physicians and patients themselves — at far less cost."

25 May 2010

Research work holds promise for biological substitute for dental implants

A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.

24 May 2010

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc have been filed.

24 May 2010

New technique designed to analyze individual immune cells may help diagnose food allergies: Study

About 30 percent of Americans believe they have food allergies. However, the actual number is far smaller, closer to 5 percent, according to a recent study commissioned by the National Institute of Allergy and Infectious Diseases. That's due in large part to the unreliability of the skin test that doctors commonly use to test for food allergies.

24 May 2010

South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians are helping doctors of the Mayo Clinic build mathematical models to fine-tune an innovative strategy to treat cancer.

24 May 2010

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $21.0 million of shares of its Series 5 Preferred Stock in a registered offering to three institutional investors (collectively, the "Initial Purchasers"). Each share of Series 5 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,500 shares of common stock at a conversion price of $0.40 per share of common stock, for a total of 52,500,000 shares of common stock.

24 May 2010

Poor survival rates in non-Hodgkin's lymphoma patients attributed to lifestyle factors

A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.

24 May 2010

Disparities exist in bone marrow transplantation

African-Americans and women are less likely than Caucasians and men to undergo bone marrow transplantation to treat cancers of the blood.

24 May 2010

Stem cell research could lead to new treatment strategies for motor neuron disease

The Motor Neurone Disease Association is funding its first ever stem cell research programme to help unlock the secrets of this fatal, neurological condition.

24 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Current research suggests that T helper-type 1 (Th1) cells, previously thought to mediate autoimmunity, may actual inhibit the development of experimental immune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), by suppressing Th17 cells.

24 May 2010

T Cell News and Research

Latest T Cell News and Research

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

A unique multi-modal atlas of human brain

Advances in health IT

Research work holds promise for biological substitute for dental implants

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

2010 ASCO Annual Meeting highlights new research findings on cancer

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

New technique designed to analyze individual immune cells may help diagnose food allergies: Study

South Dakota State University mathematicians design mathematical models to treat cancer

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Poor survival rates in non-Hodgkin's lymphoma patients attributed to lifestyle factors

Disparities exist in bone marrow transplantation

Stem cell research could lead to new treatment strategies for motor neuron disease

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in